In January, 1944, Schatz, Bugie, and Waksman' reported the isolation of a new antibacterial substance which was designated as streptomycin. In December, 1944, Feldman and Hinshaw' reported their observations on the suppressive effect of streptomycin on the human variety of microbacterium tuberculosis in guinea pigs. In January, 1946, Cooke, Dunphy, and Blake' reported in this Journal the first human case of tuberculous meningitis treated with streptomycin. At the time the article was published the patient had been observed for four months after therapy had been discontinued. She is still alive six years after the first therapy was given, she has had no relapses, and has received no further streptomycin after the initial 68 days of treatment.n From January 1, 1947, to January 1, 1951, fifty-six patients on whom a clinical diagnosis of tuberculous meningitis was made were seen at this hospital. This diagnosis was bacteriologically proven on thirty-seven patients who were treated, and the series is reported in detail (Table 1 ). An additional five were proven but died before receiving treatment, and fourteen had strong supporting evidence for the diagnosis of tuberculous meningitis, but the spinal fluid proof could not be obtained.
As the data were analyzed certain observations merited comment, namely, age of the patient, length of illness prior to admission to the hospital, the clinical status of the patient when therapy was started, latent period prior to institution of therapy, and the presence or absence of miliary tuberculosis.
Twenty (54%o) of the patients were two years of age or under. Of these, sixteen (80%o) were ill for two weeks or more; thirteen (65%o) were considered late, i.e., semicomatose or comatose, in the disease when therapy was started; twelve (60%o) had miliary tuberculosis. All twenty patients had one or more of these factors complicating their illness; all of these patients died.
When these figures were compared with some observations obtained for the seventeen children over two years of age, a striking contrast was obtained. Eight (47%) were ill for two weeks or more, a difference of 33%o; nine (53%o) were late in the disease when therapy was started, a difference of 12%o; only three (18%o) had miliary tuberculosis, a difference of 42%o in miliary tuberculosis. The four living patients are in this group.
Lincoln'M states that prior to streptomycin therapy the longest duration of tuberculous meningitis from the time of onset until death was 63 days, with the average being 19Y2 days. In a recent review of sixty-six cases LorberM found that the average length of time from the onset of symptoms until the therapy was begun was 14½2 days. He pointed out that when a disease has progressed more than two-thirds of the way through its natural course before therapy is started, one is asking a great deal of any therapy, no matter how efficient, to expect a satisfactory outcome. Though certain investigators feel that the number of days prior to therapy does parallel the clinical status when therapy is begun, a more accurate evaluation can be obtained when one considers both factors. Therefore, both the length of illness and the classification of the clinical status of the patient into early, moderate, and late stages of the disease at the time therapy was initiated has been given. Sixty-five per cent of the patients were ill two weeks or more prior to the institution of therapy. They were ill an average of nineteen days, a striking figure when compared with the average survival of 19½2 days without any therapy. Three of the four patients who are living received therapy before the fifteenth day. Four of the patients had one or more relapses. In each instance except one, when the patient was started on therapy prior to two weeks of illness, the patient has survived.
Those patients classified as early were those who had no neurological symptoms, were mainly lethargic, and were completely rational. Only five patients were in this optimal state when therapy was started. Two of these five are living. A third patient in this group survived an initial illness and one relapse, both of which were treated in the early stages, but she died during the second relapse. On the final admission she was late in the disease. The moderate patients were lethargic but not semicomatose and had neurological findings. Ten patients were in this group. They had been ill from four to fifty-two days. It is, therefore, apparent that there is not an absolute correlation between clinical status and the duration of illness. One of these patients has had one relapse returning in the moderate stage of her illness and has survived that episode. One other patient in this group survived for over a year but was critically ill when streptomycin was begun again and died in this relapse. The late patients were semicomatose or comatose. Twenty-two of the thirty-seven patients were late when therapy was begun. They had been ill from ten to sixty days. One of these patients is still under therapy. Another is the son of an itinerant laborer and was re- moved against our advice in a critical condition. All efforts to trace the family and the child have failed. The remainder of this group did not survive.
Since it was observed that an individual can progress to the late stage of the disease within ten days or less, it is of importance to consider the latent period between the time of admission and the institution of therapy. Here, as elsewhere, the indications for the beginning of streptomycin therapy have been altered. Early in the studies it was thought that bacteriological proof must be obtained before streptomycin could be given. Later it was begun after three spinal fluid examinations; now on clinical impression alone streptomycin is started, striving for bacteriological proof later.
In those cases where bacteriological proof is not immediately forthcoming, supporting evidence is derived from the spinal fluid sugar, total protein, and cell count. In tracing the contact history of the children in this series, evidence of active tuberculosis was found in an immediate member of twelve of the families. There was probable tuberculosis in five more families, but they failed to cooperate with subsequent films and examinations to confirm the initial impression. In eleven families an aunt, uncle, or grandparent had tuberculosis; in seven it was impossible to establish a contact history; in two the family survey was admittedly incomplete. There was good evidence that the contact came from an immediate member of the family or close relative in 75% of the cases. The Mantoux was positive in twenty-eight (75%o) of the children. One child had a negative tuberculin; two died prior to completing the tuberculin test through the second strength; the record was not complete for the tuberculin reactions on the other six.
In this laboratory both immediate centrifugation of the spinal fluid as well as waiting for pellicle formation is utilized; the spinal fluid is cultured on Lowenstein, Petragnani, and Dubos medium; two spinal fluid samples and two gastric washing samples are routinely inoculated into guinea pigs.
Fifteen (40%o) of the patients were clinically diagnosed as having miliary tuberculosis; nine were confirmed at autopsy; another showed residuals of a disseminated process thought to be compatible with the x-ray diagnosis of miliary tuberculosis; one diagnosed as miliary tuberculosis during life was a case of bronchogenic dissemination. In the other four, autopsies were not granted, though one had tuberculous choroiditis. Ten of the fifteen lived less than sixteen days.
From January 1, 1947, through April, 1949, streptomycin was given intramuscularly and intrathecally. The patients received 1 to 2 gms. of streptomycin intramuscularly daily, except for one patient, MG, who received 4 gms. of streptomycin daily in a final desperate attempt to save her life. Therapy was limited to sixty and later 120 days, eventually reaching a point where the clinical condition and the laboratory findings influenced the duration of therapy rather than to have a predetermined length of time. Intrathecal dosage varied considerably, ranging from 100 mgm. at first to 1 mgm. per kilogram body weight before it was discontinued completely in May, 1949. Intrathecal therapy was given daily unless technical difficulties prevented the installation of streptomycin. Promizole* was started in August, 1948, and usually 2 gms. a day were given. A blood level of 5 mgm. per cent was considered optimum.
We were unable to establish bacteriological proof from the spinal fluid examinations in fourteen patients (Table 2) . Support for the clinical diagnosis came from the family history which revealed good contact in eleven cases and probable contact in two more. The chest film was contributory in five cases. The Mantoux was positive in nine cases. Gastric washings were positive in four. Two patients in this group are living today. Tuberculous meningitis was confirmed in the four who came to postmortem examination.
REVIEW OF LITERATURE
The discouraging results obtained in the series here prompted a survey of the literature, both in English and in foreign languages. Unfortunately, much of the literature which has been written on this subject since January, 1946, cannot be readily analyzed, for most series still include unproven cases and are not reported in a manner facilitating comparative studies. In doing such an extensive study certain criteria for selection of the cases had to be established and rigidly followed. Only bacteriologically proven cases were included; unfortunately, certain series were invalidated, for the proven cases were mixed with the unproven cases with no possible means of separating them. The only other factor considered in the selection of the cases was the age. Only those cases occurring in children under 16 were included. This age was chosen because the series from here was limited to children. Table 3 lists the cases with as accurate an analysis of each case as the report would permit.
One thousand two hundred and twenty cases were found which met the two criteria. At the time the authors reported their series, 635 were alive, 584 were dead, and the outcome was undetermined from the report of one.
At least 297 had miliary tuberculosis. Inasmuch as the difficulty in establishing the diagnosis of miliary tuberculosis is well known, it is apparent that the statement in regard to the presence of miliary tuberculosis cannot be accepted as proven in all cases. Specific age for 1,029 children was given, with 286 of them being two years or under. From the information given about the patients, either in case histories or from tabulation, 580 could be classified as to their clinical status using the criteria employed earlier in this report; 177 were early in the disease, 235 were moderate, and * In the early part of this study Promizole was supplied through the courtesy of the Department of Therapeutic Development, Parke, Davis and Company, Detroit. 168 were late. Three hundred and thirty-nine patients were ill less than 15 days prior to the onset of therapy; 168 were ill over' 15 days. It was impossible to determine how long 713 had been ill. For 398 cases in the series both the duration of the illness and the clinical condition were given. It is perfectly clear that the two factors are not well correlated, the degree of variability being so great that it would be most unlikely to have the situation altered in a larger group. The standard deviation of the number of days before therapy in each clinical group is so great that considerable overlapping is indicated, even though it is not certain that the distribution is strictly normal.
Since there was great variability in the interval which elapsed from the time the clinician discontinued therapy until he reported his patients, some method of comparative study of the cases had to be devised. Four hundred and thirty-seven children, about whom no essential fact was missing, were classified as early, moderate, and late in their illness. They were then subdivided into various groups-those two years and under; those over two years; those ill 14 days or less; those ill over 14 days; and those with or without miliary tuberculosis. If a patient's condition was last reported at two months, for example, he was then omitted from the statistical calculation at the third month. Therefore, the accompanying graphs indicate the known survivors only for a given month expressed in percentage as determined by dividing the number of known survivors by the number known living plus the number known dead, i.e., the number whose history was completely known (Fig. 1) .
In all four graphs those patients two years of age and under have been combined with those over two years. This combination of patients was justified after subjecting each individual group to a statistical study which showed that one was not justified in establishing an arbitrary division of patients at two years and assuming that the prognosis was adversely influenced to a significant degree by the younger age. The method employed in this study was the application of the Chi squared test to a contingency table of monthly survival totals.
The same method was used in the following analysis of the data. Figure  1 , Graph A, shows the number of patients reported as surviving at each specific month for a 24-month period. These were the patients who were not reported as having miliary tuberculosis and were started on therapy in less than 15 days from the onset of their illness. This group of patients with the most favorable circumstances was compared with the remaining group, i.e., those who were started on therapy after the second week of illness (those in Graph B) and those who had miliary tuberculosis (those in Graphs C and D). A significantly high Chi squared figure was obtained showing that those in our presumptively most favorable Group A actually did have a better prognosis than the remainder of the series. Early-2eases Moderate-27ases te-19 lases
All those patients with miliary tuberculosis were compared with all those without miliary tuberculosis. It was found that the two groups did not show a significant variation from each other in month-by-month survival. A more minute analysis by clinical condition, i.e., early, moderate, and late stages of the disease, revealed significant differences between the miliary and nonmiliary cases in the moderate and late groups, but any difference in the early group could not be proven to be free from chance. The therapy can be grouped into three general categories: The 657 patients who received only intramuscular plus intrathecal streptomycin were compared with the 521 who received intramuscular plus intrathecal streptomycin with some adjunct therapy. Variation in the total dosage and the frequency of administration could not be taken into consideration because of the extreme complexity of the over-all therapeutic regime. It was found that there was no significant difference between the two groups as a whole. However, when those receiving a sulfone were removed from the total number receiving adjunct therapy and then compared with those receiving intramuscular plus intrathecal streptomycin, it was observed that the administration of a sulfone favorably influenced the outcome in the first few months after the administration of the medication. As time progressed, those receiving a sulfone actually faired less well as a group. Those receiving tuberculin which had been given intravenously reversed the pattern, showing a significantly adverse reaction to the tuberculin in the early months, but later on this effect disappeared and those receiving tuberculin did somewhat better after the sixth month. When those receiving intramuscular streptomycin alone were compared with those receiving intramuscular and intrathecal streptomycin without an adjunct, the variation was of no importance.
DISCUSSION
The authors recognize that certain errors in tabulation may have been introduced into this study. A genuine effort was made to obtain all the proven cases of tuberculous meningitis in children recorded in the literature since streptomycin was introduced as a therapeutic agent. It is surely obvious that this effort was unsuccessful to some degree for reasons which are apparent. From the onset of this work it was evident that lack of uniformity in reporting, even as to what might be called a therapeutic success, was to plague us as the various aspects of the over-all problem were analyzed. For this reason the method of the Chi squared test applied to contingency tables of monthly survival totals pervades all the principal calculations.
The history of the development of the present-day therapy for the purulent meningitides is an interesting one. When type specific antisera were first employed, they were introduced intrathecally in a therapeutic gesture. It was observed later that the patient's recovery was not adversely influenced if the serum was not placed directly into the central nervous system, and that actually many of the sequelae attributed to the severity of the disease were being caused by this route of administration, and that if the serum was given intravenously or intramuscularly alone, the patient had a greater opportunity for complete recovery. When the chemotherapeutic and the antibiotic agents were first used, they too were introduced intrathecally.
Actually, it is just recently that most physicians have discontinued the intrathecal administration of penicillin in pneumococcal meningitis, and of streptomycin in Hemophilus influenzae, type b, meningitis. There can be no doubt that this transition has not as yet taken place in the treatment of tuberculous meningitis, for only thirty-one out of the 1,220 patients received intramuscular treatment without intrathecal treatment.
At this hospital the children received intramuscular and intrathecal streptomycin therapy until May, 1949, at which time all intrathecal administration was discontinued. This change in therapy was initiated because data had been accumulating to indicate that significant streptomycin levels were obtained in the spinal fluid from intramuscular streptomycin alone; certain serious complications from the intrathecal injection of streptomycin were being observed, and the rare case given intramuscular streptomycin alone had been reported as doing satisfactorily. Though more of the survivors from this hospital appear in the series receiving intramuscular streptomycin alone, the number is too small to be of significance.
The length of survival of those under two years of age was compared with that observed in those over two years old receiving treatment in this hospital. Those under two had a shorter survival time than those over two. This was attributed to the presence of other adverse circumstances found in the younger children, namely, the greater length of time before the patient was brought to the hospital for therapy, the more serious clinical condition, and the more frequent presence of miliary tuberculosis. This fact could not be directly compared with the observations made in the literature because those tables had to be established on the percentage of survivals reported.
From the literature it was of no significance to establish an arbitrary dividing point at the age of two years, yet it was possible to show that each individual factor being brought to bear upon the child under two was exerting a deleterious influence. Perhaps inability to prove this difference in response from the literature may be explained by the natural tendency to report therapeutic successes rather than failures; therefore, the figures may be inadvertently weighted.
In both this series and in the literature there was good evidence that the duration of illness inversely influenced the outcome. This would seem obvious. But when the duration of illness was compared with the clinical status, there was little correlation, and it could be shown that the clinical status of the patient at the time of therapy was instituted was of great significance in determining the ultimate outcome.
The presence of miliary tuberculosis adversely influenced the patients seen in this hospital. When the large group was studied, it was surprising to find that the presence of miliary tuberculosis does not influence the outcome if the patient comes to therapy early in the disease, but in the later stages miliary tuberculosis materially alters the outcome. This may be explained by the medication favorably influencing the disseminated disease early in its course, but once it has become well established, medication cannot reverse the process. It should be stated that in the interpretation of the graphs for the influence of miliary tuberculosis on the outcome, the early cases in Graph D were not included because the number of patients was too small.
The beneficial influence of sulfone therapy is interesting in light of the observations of Lincoln5" on the favorable influence Promizole had upon children with miliary tuberculosis alone. It is tenable that the two drugs, streptomycin and a sulfone, do complement each other to the patient's advantage. It is difficult to explain the apparent late adverse effect of the sulfones on the ratio of the survivors.
The early adverse influence of intravenous tuberculin was not anticipated. One can speculate that the tuberculin served to "light up" the tuberculous process to so great a degree that the patient was unable to handle the additional insult.
Though it could be shown that there was no variation beyond that introduced by chance in the comparison of the survival totals for the patients receiving intramuscular streptomycin alone and those receiving intramuscular plus intrathecal streptomycin, it is impossible to accept this as a valid observation, since the total group receiving intramuscular streptomycin alone was too small. SUMMARY Forty-one additional proven cases have been added to the literature. After April, 1949, no patient with tuberculous meningitis at this hospital has received intrathecal medication.
One thousand two hundred and twenty cases of proven tuberculous meningitis in children have been analyzed.
It was possible to demonstrate that those children under two years of age had a poor prognosis from this series, but an arbitrary delineation at the age of two could not be established in those cases taken from the literature. An explanation for this is offered.
The clinical status of the patient is of more value than the duration of illness in estimating the prognosis.
Miliary tuberculosis was shown to influence adversely those who were moderately ill and those who were late in their illness, but it was not possible to demonstrate that it exerted an adverse influence in those treated early.
Sulfones favorably influenced the early outcome of the patients studied in the literature. Intravenous tuberculin adversely influenced the early outcome of the patients studied in the literature.
